SNU Bundang Hospital and Cipherome, Inc. Memorandum of Understanding for cooperation in personalized medicine

Collaboration to create the Precision Medicine Research Platform at the SNUBH Institute for Biomedical Research

San Jose, Calif., November 16, 2022– (working wire) – The Biomedical Research Institute of Seoul National University (SNU) Hospital announced that it entered into a Memorandum of Understanding on November 15, 2022 to standardize clinical genomic research using Cipherome’s Precision Medicine Research Platform at the Center for Precision Medicine.

This press release features multimedia. View the full version here: https://www.businesswire.com/news/home/20221116006039/ar/

The Biomedical Research Institute of Seoul National University Bundang Hospital has signed a Memorandum of Understanding (MOU) with Cipherome, Inc. , a precision medicine biological project company based in Silicon Valley, USA, to build a precision medicine research platform. (Photo: Business Wire)

The Center for Precision Medicine, which is an integral part of the Seoul National University Bundang Hospital’s Future Innovation Research Department in supporting medical staff with genome education and research support programs, is currently establishing large-scale collections based on the hospital’s human biobank.

At the signing ceremony on November 15thThe tenthJi Soo Kim (Chairman and Chief Research Officer of the Institute of Biomedical Research at Seoul National University Bundang Hospital), Ji Hyun Kim (Chair, Department for Future Innovation Research), Jung Hoon Eun (Director, Center for Precision Medicine), Jinho Kim and Sejeon Lee (Professors At the Center for Precision Medicine), Elsung Lee (CEO of Cipherome), Min Kim (CTO at Cipherome), and others comment on the future direction of personalized medicine using clinic genomic factors.

Given the strong need for tools to organize, screen, and perform genomic and clinical data research and the lack of accessible tools for clinical researchers, Cipherome has commercialized its data analysis development system, the Compass Platform, to enable clinical researchers to conduct complex research. Data science tasks—from statistical analysis to machine learning training—on genomic and clinical data efficiently and quickly. The primary aim is to shorten the time to results of a population-wide extrapolation using UK BioBank data.

Ji-Soo Kim, Head of the Biomedical Research Institute of Seoul National University Bundang Hospital, stated, “Through this MoU with Cipherome, we will actively support research and development in the field of precision medicine based on massive clinical and genomic data. We will continue to strengthen our research capacity to take the lead in the precision medicine market.” Globalism “.

Cipherome CEO Ilsung Lee also said, “Our collaboration with the Biomedical Research Institute of Seoul National University Bundang Hospital is key to achieving the impact and adoption of clinical genomics as the institute plays a key role in advancing the medical industry through research and development of innovative medical technology.” We hope that this MoU will improve the competitiveness of precision medicine research and the capabilities of Seoul National Bundang University Hospital.”

The Korean press release can be found here: http://www.bosa.co.kr/news/articleView.html?idxno=2185045

Please direct questions to: info@cipherome.com

About Cipherome

Cipherome is an AI and bioinformatics company focused on personalizing medicines to reduce adverse drug interactions using patented technology. Our team brings extensive experience in medicine, drug development, bioinformatics, artificial intelligence, and award-winning product development to address a $100 billion-plus problem in healthcare: drug response variance.

The Xentinel® Compass platform can analyze large-scale genomic and clinical data in a fast and easy way. Using its unique modular architecture, the platform is highly configurable and extensible for extracting and transforming data from various clinic genomic big data sources, including the UK BioBank. As a comprehensive analysis platform that provides comprehensive functionality in ensemble selection, feature engineering, exploratory data analysis, statistical analysis, machine learning, and visualization, this platform enhances researchers’ access to biobank data and provides the most efficient path to data insight. While the platform has many applications, its current primary focus is maximizing the efficiency of clinical genomics data analysis and accelerating new drug development and treatment research. Currently, its applications are being promoted through collaborations with university hospitals, research institutions as well as global pharmaceutical companies. The Cipherome point-of-care platform is being used to customize treatment for post-heart attack and diabetic peripheral arterial disease patients in So. Texas, Illinois, and New Jersey.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221116006039/ar/

Contacts

info@cipherome.com

Leave a Comment